Eyenovia, Inc. EYEN · Stock Open Eyenovia, Inc. in new tab
Eyenovia, Inc. Analysis (EYEN)
Is Eyenovia, Inc. a good investment? Eyenovia, Inc. (EYEN) is currently trading at 7.56 USD.
Earnings Schedule: Eyenovia, Inc. is expected to release its next earnings report on Nov. 10, 2025. The market consensus estimate for Forward EPS is -0.53.
Investor FAQ
Does Eyenovia, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Eyenovia, Inc.?
Eyenovia, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2025. The company currently has a trailing EPS of -42.65.
Company Profile
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 3, 2025 | 1:100 |
Community Discussion